CARBIDOPA AND LEVODOPA
Total Payments
$1.6M
Transactions
376
Doctors
1
Companies
1
Payment Trends by Year
| Year | Amount | Transactions | Doctors |
|---|---|---|---|
| 2022 | $373,196 | 62 | 1 |
| 2021 | $1.2M | 314 | 0 |
Payments by Nature
| Nature of Payment | Amount | Transactions | Share |
|---|---|---|---|
| Unspecified | $1.6M | 376 | 100.0% |
Research Studies & Clinical Trials
| Study Name | Sponsor | Amount | Doctors |
|---|---|---|---|
| A Randomized Controlled Study to Compare the Safety and Efficacy of IPX203 With Immediate-Release Carbidopa-Levodopa in Parkinson's Disease Patients With Motor Fluctuations | Amneal Pharmaceuticals LLC | $1.6M | 1 |
Top Doctors Receiving Payments for CARBIDOPA AND LEVODOPA
| Doctor | Specialty | Location | Total | Records |
|---|---|---|---|---|
| Unknown | — | Wilmington, DE | $1.6M | 375 |
| , M.D | Neurology | Commack, NY | $2,000 | 1 |
Ad
Manufacturing Companies
Product Information
- Type Drug
- Total Payments $1.6M
- Total Doctors 1
- Transactions 376
About CARBIDOPA AND LEVODOPA
CARBIDOPA AND LEVODOPA is a drug associated with $1.6M in payments to 1 healthcare providers, recorded across 376 transactions in the CMS Open Payments database. The primary manufacturer is Amneal Pharmaceuticals LLC.
Payment data is available from 2021 to 2022. In 2022, $373,196 was paid across 62 transactions to 1 doctors.
The most common payment nature for CARBIDOPA AND LEVODOPA is "Unspecified" ($1.6M, 100.0% of total).
CARBIDOPA AND LEVODOPA is associated with 1 research study, including "A Randomized Controlled Study to Compare the Safety and Efficacy of IPX203 With Immediate-Release Carbidopa-Levodopa in Parkinson's Disease Patients With Motor Fluctuations" ($1.6M).